Cargando…
Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?
OBJECTIVES: The aim of the study was to evaluate the efficacy of dual therapy with lamivudine (3TC), with dose adjustment for renal function, and dolutegravir (DTG) in a subgroup of patients fully suppressed on treatment who were switched because of concerns about comorbidity and toxicity on their c...
Autores principales: | Tan, M, Johnston, S, Nicholls, J, Gompels, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790693/ https://www.ncbi.nlm.nih.gov/pubmed/31338933 http://dx.doi.org/10.1111/hiv.12781 |
Ejemplares similares
-
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017) -
Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV
por: Ergen, Pınar, et al.
Publicado: (2022) -
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022) -
1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023) -
No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial
por: Li, Jonathan Z, et al.
Publicado: (2019)